High specificity but low sensitivity of mutation-specific antibodies against EGFR mutations in non-small-cell lung cancer

Clarifying the Spectrum of Driver Oncogene Mutations in Biomarker-Verified Squamous Carcinoma of Lung: Lack of EGFR/KRAS and Presence of PIK3CA/AKT1 Mutations

(2012) N. Rekhtman et al.   CLINICAL CANCER RESEARCH

A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry

(2012) Bárbara Angulo et al.   PLoS One

Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non–Small-Cell Lung Cancer in Asia (IPASS)

(2011) Masahiro Fukuoka et al.   JOURNAL OF CLINICAL ONCOLOGY

EGFR Gene Alterations in a Norwegian Cohort of Lung Cancer Patients Selected for Surgery

(2011) Åslaug Helland et al.   Journal of Thoracic Oncology

Association of the Expression of Mutant Epidermal Growth Factor Receptor Protein as Determined with Mutation-Specific Antibodies in Non-small Cell Lung Cancer with Progression-Free Survival after Gefitinib Treatment

(2011) Koichi Azuma et al.   Journal of Thoracic Oncology

Detection of EGFR mutations with mutation-specific antibodies in stage IV non-small-cell lung cancer

(2011) Sara Simonetti et al.   Journal of Translational Medicine

The challenge of NSCLC diagnosis and predictive analysis on small samples. Practical approach of a working group

(2011) Erik Thunnissen et al.   LUNG CANCER

Immunohistochemical Detection of EGFR Mutation Using Mutation-Specific Antibodies in Lung Cancer

(2010) A. Kitamura et al.   CLINICAL CANCER RESEARCH

Molecular Diagnosis of Activating EGFR Mutations in Non-Small Cell Lung Cancer Using Mutation-Specific Antibodies for Immunohistochemical Analysis

(2010) A. Kawahara et al.   CLINICAL CANCER RESEARCH

Assessment of EGFR Mutation Status in Lung Adenocarcinoma by Immunohistochemistry Using Antibodies Specific to the Two Major Forms of Mutant EGFR

(2010) Marie Brevet et al.   JOURNAL OF MOLECULAR DIAGNOSTICS

Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer

(2010) Sarah Park et al.   Journal of Thoracic Oncology

Novel Epidermal Growth Factor Receptor Mutation-Specific Antibodies for Non-small Cell Lung Cancer: Immunohistochemistry as a Possible Screening Method for Epidermal Growth Factor Receptor Mutations

(2010) Yasufumi Kato et al.   Journal of Thoracic Oncology

Prognostic and Predictive Value of Epidermal Growth Factor Receptor Tyrosine Kinase Domain Mutation Status and Gene Copy Number for Adjuvant Chemotherapy in Non-small Cell Lung Cancer

(2010) Ming-Sound Tsao et al.   Journal of Thoracic Oncology

The usefulness of mutation-specific antibodies in detecting epidermal growth factor receptor mutations and in predicting response to tyrosine kinase inhibitor therapy in lung adenocarcinoma

(2010) Yoshiki Kozu et al.   LUNG CANCER

Usefulness of tissue microarrays for assessment of protein expression, gene copy number and mutational status of EGFR in lung adenocarcinoma

(2010) Marius I. Ilie et al.   VIRCHOWS ARCHIV

HER2 diagnostics in gastric cancer—guideline validation and development of standardized immunohistochemical testing

(2010) Josef Rüschoff et al.   VIRCHOWS ARCHIV

Mutation-Specific Antibodies for the Detection of EGFR Mutations in Non-Small-Cell Lung Cancer

(2009) J. Yu et al.   CLINICAL CANCER RESEARCH

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial

(2009) Tetsuya Mitsudomi et al.   LANCET ONCOLOGY

Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer

(2009) Rafael Rosell et al.   NEW ENGLAND JOURNAL OF MEDICINE

Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma

(2009) Tony S. Mok et al.   NEW ENGLAND JOURNAL OF MEDICINE

High resolution melting analysis for rapid and sensitive EGFR and KRAS mutation detection in formalin fixed paraffin embedded biopsies

(2008) Hongdo Do et al.   BMC CANCER

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403)

(2008) K Tamura et al.   BRITISH JOURNAL OF CANCER

Epidermal growth factor receptor immunohistochemistry

(2008) Fred R. Hirsch et al.   CANCER

Biomarkers of Response to Epidermal Growth Factor Receptor Inhibitors in Non–Small-Cell Lung Cancer Working Group: Standardization for Use in the Clinical Trial Setting

(2008) David A. Eberhard et al.   JOURNAL OF CLINICAL ONCOLOGY

First-Line Gefitinib in Patients With Advanced Non–Small-Cell Lung Cancer Harboring SomaticEGFRMutations

(2008) Lecia V. Sequist et al.   JOURNAL OF CLINICAL ONCOLOGY

Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method

(2008) Ruta Gupta et al.   MODERN PATHOLOGY